Internet Resources for Your Patients
Internet Resources for Your Patients
There are many useful resources available online that may help your patients understand and manage their treatment with TREMFYA® and their disease. You may find the websites listed here helpful as referrals in educating your patients about their condition.
TREMFYA® Patient Website
This website contains information about TREMFYA®.
American Academy of Dermatology
The American Academy of Dermatology is dedicated to providing dermatologists with the information and resources they need to serve their patients. Patients can learn more about dermatologists and the conditions they treat.
The Arthritis Foundation
The Arthritis Foundation offers guidance and support for those living with all forms of arthritis, including psoriatic arthritis. Also available are tools, resources, and opportunities to get involved and connect to local support.
The online home of the Arthritis Foundation’s Arthritis Today magazine is a great source of tips and information for people living with all forms of arthritis, including psoriatic arthritis.
CreakyJoints is a non-profit organization that provides a support community for patients and their caregivers. CreakyJoints members receive newsletters, opportunities to participate in workshops, and special events and programs, which provide educational materials about psoriatic arthritis.
National Psoriasis Foundation
The National Psoriasis Foundation (NPF) is a non-profit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected.
TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.
The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.